Bioengineered chimeric tRNA/pre-miRNAs as prodrugs in cancer therapy

Area of Science:

• Oncology
• Molecular Biology
• Biotechnology

Background:

• Non-coding RNAs (ncRNAs), particularly microRNAs (miRNAs), play crucial roles in cancer pathology and tumorigenesis.
• Current miRNA-based cancer therapies predominantly rely on chemically synthesized miRNAs, which can have limitations in safety and biological activity.
• Bioengineered miRNAs present an alternative to synthetic mimics, potentially overcoming issues related to folding, safety, and efficacy.

Purpose of the Study:

• To review the advancements in bioengineered microRNAs (miRNAs) for cancer therapy.
• To explore the potential of bioengineered miRNAs as biological prodrugs for targeted cancer treatment.
• To discuss novel approaches, including chimeric tRNA/pre-miRNAs, in the field of bioengineered miRNA therapeutics.

Main Methods:

• Utilizing microbial fermentation for the economical production of bioengineered miRNAs.
• Developing bioengineered chimeric miRNAs for selective processing in cancer cells.
• Investigating the use of various carriers for efficient delivery of bioengineered miRNAs.

Main Results:

• Bioengineered miRNAs produced via microbial fermentation offer a cost-effective and potentially safer alternative to synthetic miRNAs.
• Chimeric miRNAs can be engineered for targeted delivery and selective activation within cancer cells.
• This approach holds promise for developing novel, highly specific cancer therapeutics.

Conclusions:

• Bioengineered miRNAs represent a promising new avenue for cancer therapy, offering improved safety and specificity.
• Economical production through microbial fermentation makes this approach scalable and accessible.
• Further research into bioengineered chimeric miRNAs, including tRNA/pre-miRNA constructs, is warranted for advancing cancer treatment strategies.